Acorn Bioventures has led a series B round for the cancer-focused biopharmaceutical spinout of CU Boulder.
OnKure, a US-based oncology therapeutics spinout of University of Colorado Boulder, secured $55m in a series B round today led by Acorn Bioventures.
Cormorant Asset Management, Surveyor Capital, Samsara BioCapital, Perceptive Advisors and funds and accounts managed by BlackRock also took part in the round.
Founded in 2011, OnKure is working on small molecule drugs that delay resistance to other targeted cancer therapies and exploit synthetic lethalities. Its lead asset, OKI-179, is now set to enter phase 2…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
